A Study to Evaluate the Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% BID Compared to Vehicle in the Treatment of Bacterial Conjunctivitis.

Trial Profile

A Study to Evaluate the Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% BID Compared to Vehicle in the Treatment of Bacterial Conjunctivitis.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 16 Feb 2013

At a glance

  • Drugs Besifloxacin (Primary)
  • Indications Bacterial infections; Conjunctivitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 May 2012 Results were published in Clinical Drug Investigation.
    • 28 Mar 2012 Trial phase changed from III to II/III as reported by ClinicalTrials.gov.
    • 28 Mar 2012 Actual patient number changed from 272 to 474 according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top